BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31700175)

  • 1. Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.
    Kim JW; Marquez CP; Kostyrko K; Koehne AL; Marini K; Simpson DR; Lee AG; Leung SG; Sayles LC; Shrager J; Ferrer I; Paz-Ares L; Gephart MH; Vicent S; Cochran JR; Sweet-Cordero EA
    Nat Med; 2019 Nov; 25(11):1783-1795. PubMed ID: 31700175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stromal Hedgehog pathway activation by IHH suppresses lung adenocarcinoma growth and metastasis by limiting reactive oxygen species.
    Kasiri S; Chen B; Wilson AN; Reczek A; Mazambani S; Gadhvi J; Noel E; Marriam U; Mino B; Lu W; Girard L; Solis LM; Luby-Phelps K; Bishop J; Kim JW; Kim J
    Oncogene; 2020 Apr; 39(16):3258-3275. PubMed ID: 32108165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering a potent receptor superagonist or antagonist from a novel IL-6 family cytokine ligand.
    Kim JW; Marquez CP; Sperberg RAP; Wu J; Bae WG; Huang PS; Sweet-Cordero EA; Cochran JR
    Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14110-14118. PubMed ID: 32522868
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
    Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
    Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
    Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
    Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
    Mohrherr J; Haber M; Breitenecker K; Aigner P; Moritsch S; Voronin V; Eferl R; Moriggl R; Stoiber D; Győrffy B; Brcic L; László V; Döme B; Moldvay J; Dezső K; Bilban M; Popper H; Moll HP; Casanova E
    Int J Cancer; 2019 Dec; 145(12):3376-3388. PubMed ID: 31407334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.
    Unni AM; Harbourne B; Oh MH; Wild S; Ferrarone JR; Lockwood WW; Varmus H
    Elife; 2018 Nov; 7():. PubMed ID: 30475204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotrophin-like cytokine factor 1 (CLCF1) and neuropoietin (NP) signalling and their roles in development, adulthood, cancer and degenerative disorders.
    Sims NA
    Cytokine Growth Factor Rev; 2015 Oct; 26(5):517-22. PubMed ID: 26198769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS-G12D mutation and P53 knockout.
    Zhang M; Jiang N; Cui R; Du S; Ou H; Chen T; Ge R; Ma D; Zhang J
    J Cell Mol Med; 2019 Oct; 23(10):6978-6988. PubMed ID: 31410985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor of Differentiation-1 Sustains Mutant
    Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
    Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice.
    Rosenfeld YB; Krumbein M; Yeffet A; Schiffmann N; Mishalian I; Pikarsky E; Oberman F; Fridlender Z; Yisraeli JK
    Oncogene; 2019 May; 38(21):4169-4181. PubMed ID: 30700831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
    Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
    J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independent of its catalytic activity.
    Huang W; Ray P; Ji W; Wang Z; Nancarrow D; Chen G; Galbán S; Lawrence TS; Beer DG; Rehemtulla A; Ramnath N; Ray D
    J Biol Chem; 2020 May; 295(18):5906-5917. PubMed ID: 32165494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Chen X; Wang Y; Qu X; Bie F; Wang Y; Du J
    Future Oncol; 2021 Feb; 17(5):565-579. PubMed ID: 33406903
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.